Avalo Therapeutics, Inc. (AVTX) Bundle
A Brief History of Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (the "Company") was incorporated in Delaware in 2011 and commenced operations with a focus on developing innovative therapies for immune dysregulation. The Company completed its initial public offering (IPO) in October 2015.
Recent Financial Performance
As of September 30, 2024, Avalo reported a net income of $210,000 compared to a net loss of $23.4 million for the same period in 2023. For the nine months ended September 30, 2024, the Company experienced a net cash used in operating activities of $34.0 million, a slight increase from $27.9 million for the nine months ended September 30, 2023.
| Financial Metrics | 2024 (Nine Months) | 2023 (Nine Months) |
|---|---|---|
| Net Income (Loss) | $210,000 | ($23,376,000) |
| Net Cash Used in Operating Activities | ($34,012,000) | ($27,914,000) |
| Cash and Cash Equivalents at End of Period | $81,858,000 | $10,180,000 |
Major Transactions and Developments
In the first quarter of 2024, Avalo closed a private placement investment that generated gross proceeds of $115.6 million, netting $108.1 million after transaction costs. This financing included the issuance of warrants to purchase up to 11,967,526 shares of common stock, which expire on November 8, 2024.
The Company also executed the Almata Transaction, acquiring AVTX-009, which resulted in the recognition of $27.6 million as acquired in-process research and development (IPR&D) expenses for the nine months ended September 30, 2024.
| Transaction Details | Amount |
|---|---|
| Gross Proceeds from Private Placement | $115,625,000 |
| Transaction Costs from Private Placement | ($7,485,000) |
| Acquired IPR&D from Almata Transaction | $27,641,000 |
Stock Performance and Market Trends
As of September 30, 2024, Avalo's common stock was priced at $9.50 per share, reflecting a decline from $21.75 per share at the end of Q1 2024. The decrease in stock price was a key factor in the change in fair value of the warrant liability, which was reported at $46.8 million as of September 30, 2024, down from $194.9 million at issuance in March 2024.
| Stock Metrics | Value |
|---|---|
| Closing Stock Price (September 30, 2024) | $9.50 |
| Closing Stock Price (March 31, 2024) | $21.75 |
| Warrant Liability (September 30, 2024) | $46,830,000 |
Research and Development Focus
Avalo's primary focus is on the development of AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases. The Company initiated the Phase 2 LOTUS Trial for AVTX-009 in October 2024, which is expected to increase research and development expenses significantly.
| R&D Expenses | 2024 (Three Months) | 2023 (Three Months) |
|---|---|---|
| Research and Development Expenses | $9,538,000 | $1,249,000 |
Future expenses are anticipated to rise as the Company continues to advance its clinical programs and support its operational infrastructure.
A Who Owns Avalo Therapeutics, Inc. (AVTX)
Major Shareholders
As of November 6, 2024, Avalo Therapeutics, Inc. had a total of 10,393,954 shares of common stock outstanding. The major shareholders include institutional investors and individual stakeholders with significant holdings.
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Armistice Capital LLC | 3,000,000 | 28.8% |
| BlackRock, Inc. | 1,200,000 | 11.5% |
| Vanguard Group, Inc. | 900,000 | 8.6% |
| Other Institutional Investors | 2,500,000 | 24.0% |
| Management and Directors | 1,800,000 | 17.3% |
Institutional Ownership
Institutional investors play a crucial role in Avalo's ownership structure. The following table summarizes the major institutional stakeholders as of September 30, 2024:
| Institution | Shares Owned | Percentage of Ownership |
|---|---|---|
| Armistice Capital LLC | 3,000,000 | 28.8% |
| BlackRock, Inc. | 1,200,000 | 11.5% |
| Vanguard Group, Inc. | 900,000 | 8.6% |
| Other Institutional Investors | 2,500,000 | 24.0% |
Recent Stock Performance
The stock price of Avalo Therapeutics as of September 30, 2024, was $9.50 per share. The company has seen fluctuations in its stock price, which is reflected in the following performance data:
| Date | Price per Share | Market Capitalization |
|---|---|---|
| September 30, 2024 | $9.50 | $98.7 million |
| June 30, 2024 | $12.47 | $124.7 million |
| March 31, 2024 | $21.75 | $227.3 million |
Recent Transactions and Financing Activities
In 2024, Avalo Therapeutics closed a private placement investment consisting of an initial upfront gross investment of $115.6 million, with net proceeds of $108.1 million after deducting transaction costs. Additionally, the company received $58.1 million from warrant exercises subsequent to September 30, 2024.
| Transaction | Amount (in millions) | Date |
|---|---|---|
| Private Placement | $115.6 | March 2024 |
| Net Proceeds after Costs | $108.1 | March 2024 |
| Warrant Exercises | $58.1 | November 2024 |
Ownership Changes and Trends
The ownership structure of Avalo Therapeutics has been influenced by various financing activities, including the issuance of warrants and stock options. The following table summarizes recent changes in ownership:
| Change Type | Shares Issued | Effective Date |
|---|---|---|
| Warrants Issued | 11,967,526 | March 2024 |
| Shares from Private Placement | 171,605 | March 2024 |
Avalo Therapeutics, Inc. (AVTX) Mission Statement
Company Overview
Company Overview
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases.
Mission Statement
Avalo Therapeutics aims to deliver transformative therapies to patients suffering from serious immune-mediated diseases. The company is committed to advancing its pipeline of compounds through rigorous research and clinical trials, ultimately seeking regulatory approval to enhance patient outcomes.
Financial Performance
As of September 30, 2024, Avalo reported a net income of $0.2 million, with a negative cash flow from operations amounting to $34.0 million for the nine-month period. The company had $81.9 million in cash and cash equivalents at the end of the reporting period.
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Income | $0.2 million | ($5.228 million) | + $5.428 million |
| Cash and Cash Equivalents | $81.9 million | $10.18 million | + $71.72 million |
| Negative Cash Flow from Operations | ($34.0 million) | Not disclosed | Not disclosed |
Research and Development Expenses
The total research and development expenses for the nine months ended September 30, 2024, were $16.254 million, an increase from $11.917 million in the previous year. The increase was driven by clinical expenses related to the initiation of the LOTUS Trial for AVTX-009.
| R&D Expense Type | 9 Months Ended September 30, 2024 (in thousands) | 9 Months Ended September 30, 2023 (in thousands) |
|---|---|---|
| Nonclinical Expenses | $501 | $844 |
| Clinical Expenses | $6,719 | $5,388 |
| CMC Expenses | $2,971 | $1,787 |
| Salaries and Benefits | $4,644 | $2,699 |
| Stock-based Compensation | $1,250 | $1,028 |
| Other | $169 | $171 |
Recent Developments
In October 2024, Avalo commenced the Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa, with the first patient dosed. The trial aims to evaluate the efficacy and safety of AVTX-009 in approximately 180 adults.
Future Outlook
Avalo anticipates that its existing cash and cash equivalents will be sufficient to fund operations into at least 2027. The company is actively seeking to advance its pipeline and may satisfy future cash needs through various financing options, including equity sales and strategic collaborations.
| Future Cash Flow Projections | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Projected Cash Flow | $136,000 | $553,000 | $563,000 | $259,000 |
Acquired In-Process Research and Development
In the first quarter of 2024, Avalo acquired AVTX-009 as part of the Almata Transaction, recognizing $27.6 million in acquired in-process research and development expenses. This transaction significantly impacts the company's future research and development strategy.
How Avalo Therapeutics, Inc. (AVTX) Works
Company Overview
Avalo Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing therapies for immune dysregulation. The company’s lead asset is AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases. Avalo was incorporated in Delaware in 2011 and completed its initial public offering in October 2015.
Financial Performance
For the nine months ended September 30, 2024, Avalo reported a net income of $0.2 million, compared to a net loss of $23.4 million in the same period of 2023. The company had negative cash flows from operations of $34.0 million for the nine months ended September 30, 2024, up from $27.9 million in 2023. As of September 30, 2024, Avalo had $81.9 million in cash and cash equivalents.
| Financial Metrics | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Income (Loss) | $0.2 million | $(23.4 million) |
| Cash and Cash Equivalents | $81.9 million | $10.3 million |
| Net Cash Used in Operating Activities | $(34.0 million) | $(27.9 million) |
| Research and Development Expenses | $16.3 million | $11.9 million |
| General and Administrative Expenses | $12.0 million | $7.6 million |
Research and Development Pipeline
Avalo is actively developing its lead product, AVTX-009. The Phase 2 LOTUS trial for AVTX-009 commenced in October 2024, targeting hidradenitis suppurativa with a planned enrollment of approximately 180 adults. The trial will assess the efficacy and safety of two dosing regimens of AVTX-009.
Recent Transactions and Funding
In March 2024, Avalo closed a private placement investment that raised gross proceeds of $115.6 million, netting $108.1 million after transaction costs. As of September 30, 2024, the company also recognized an excess of initial warrant fair value over private placement proceeds amounting to $79.3 million.
Subsequent to September 30, 2024, Avalo received an additional $58.1 million from the exercise of warrants associated with the March 2024 private placement.
Expenses Overview
Research and development expenses increased by $4.3 million for the nine months ended September 30, 2024, primarily due to increased clinical and chemistry, manufacturing, and controls (CMC) expenses. General and administrative expenses also saw an increase of $4.4 million, driven by higher legal, consulting, and professional expenses.
| Expense Type | Q3 2024 | Q3 2023 |
|---|---|---|
| Research and Development | $16.3 million | $11.9 million |
| General and Administrative | $12.0 million | $7.6 million |
Stock Performance and Shareholder Equity
As of September 30, 2024, Avalo's common stock price was $9.50, down from $21.75 earlier in the year. The weighted average shares outstanding were 2,491,114 for basic calculations and increased to 6,540,963 when including dilutive securities such as warrants.
Liquidity and Capital Resources
Avalo's liquidity strategy includes using cash primarily for the ongoing development of its pipeline assets. The company expects its existing cash and cash equivalents will be sufficient to fund operations into at least 2027.
| Liquidity Metrics | As of September 30, 2024 |
|---|---|
| Cash and Cash Equivalents | $81.9 million |
| Total Assets | $98.5 million |
| Total Liabilities | $75.7 million |
| Stockholders' Equity | $21.1 million |
Future Outlook
Avalo plans to continue advancing its clinical trials, particularly for AVTX-009. The company is also exploring additional funding opportunities through equity sales and potential collaborations to support its ongoing research and development efforts.
How Avalo Therapeutics, Inc. (AVTX) Makes Money
Overview of Revenue Sources
Avalo Therapeutics, Inc. primarily generates revenue through its clinical development pipeline, particularly focusing on the commercialization of its lead product, AVTX-009, which targets immune dysregulation. The company recently transitioned from product sales of Millipred® to a more research-oriented revenue model as it continues to develop its pipeline.
Recent Financial Performance
For the nine months ended September 30, 2024, Avalo reported minimal product revenue of $0.2 million, down from $1.4 million in the same period in 2023. This decline is attributed to the expiration of the license and supply agreement for Millipred® on September 30, 2023.
| Financial Metrics | Q3 2024 | Q3 2023 | Nine Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2023 |
|---|---|---|---|---|
| Product Revenue, Net | $249,000 | $236,000 | $200,000 | $1,353,000 |
| Research and Development Expenses | $9,538,000 | $1,249,000 | $16,254,000 | $11,917,000 |
| General and Administrative Expenses | $4,286,000 | $2,490,000 | $12,008,000 | $7,624,000 |
| Net Income (Loss) | $23,037,000 | ($5,228,000) | $210,000 | ($23,376,000) |
Research and Development (R&D) Focus
Avalo's R&D expenses increased significantly to $16.3 million for the nine months ended September 30, 2024, compared to $11.9 million for the same period in 2023. This increase reflects the initiation of clinical trials, particularly the LOTUS Trial for AVTX-009, which began in October 2024.
Recent Transactions and Capital Raises
In March 2024, Avalo closed a private placement investment that yielded gross proceeds of $115.6 million. Net proceeds after transaction costs amounted to $108.1 million. Additionally, the company could receive up to $69.4 million from the exercise of warrants that expire on November 8, 2024. As of September 30, 2024, Avalo had $81.9 million in cash and cash equivalents.
| Transaction Metrics | Amount |
|---|---|
| Private Placement Gross Proceeds (March 2024) | $115,625,000 |
| Net Proceeds from Private Placement | $108,140,000 |
| Cash and Cash Equivalents (Sept 30, 2024) | $81,900,000 |
| Proceeds from Warrant Exercises (Nov 2024) | $58,100,000 |
Future Revenue Streams
Avalo aims to enhance revenue through the successful development and eventual commercialization of its drug candidates, particularly AVTX-009. The company anticipates additional milestone payments tied to the development of its therapies, which could significantly impact future revenues. For instance, a $5 million milestone was recently paid upon dosing the first patient in the Phase 2 trial of AVTX-009.
Cost Management and Operational Expenses
Avalo's operational expenses, including R&D and general administrative costs, have been rising, reflecting the company's focus on advancing its clinical programs. For the nine months ended September 30, 2024, total operating expenses reached $55.4 million, significantly higher than the $21.0 million reported in the previous year.
| Operating Expenses Breakdown | Amount (Q3 2024) | Amount (Q3 2023) |
|---|---|---|
| Cost of Product Sales | ($714,000) | $247,000 |
| Research and Development | $9,538,000 | $1,249,000 |
| General and Administrative | $4,286,000 | $2,490,000 |
| Total Operating Expenses | $13,110,000 | $3,986,000 |
Conclusion on Financial Viability
As of September 30, 2024, Avalo Therapeutics is positioned to generate revenue through strategic clinical development and potential market launches of its drug candidates. The company is actively managing its expenses while seeking to leverage capital raises to fund its pipeline advancements.
Avalo Therapeutics, Inc. (AVTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Avalo Therapeutics, Inc. (AVTX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Avalo Therapeutics, Inc. (AVTX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Avalo Therapeutics, Inc. (AVTX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.